1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,995 | 1,010 | 15.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 04.06. | ABBISKO-B Subsidiary Presents New Progress in Irpagratinib Drug Development at PAGE Meeting | 1 | AASTOCKS | ||
| 04.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS A NOVEL JOINT MODELING FRAMEWORK FOR ABSK-011 (IRPAGRATINIB) IN HCC PATIENTS ... | 1 | HKEx | ||
| 20.05. | ABBISKO-B (02256): ELEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | - | HKEx | ||
| 20.05. | ABBISKO-B (02256): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026 AND AMENDMENTS TO THE ARTICLES | - | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 28.04. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): NOTICE OF THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES RE-ELECTION OF DIRECTORS RE-APPOINTMENT OF AUDITOR ... | 1 | HKEx | ||
| 28.04. | ABBISKO-B (02256): PROPOSED AMENDMENTS TO THE TENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE ELEVENTH AMENDED ... | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 28.04. | ABBISKO-B (02256): 2025 ANNUAL REPORT | - | HKEx | ||
| 23.04. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS SHOWCASES SIX RESEARCH ADVANCES AT 2026 AACR, HIGHLIGHTING PAN-KRAS, 4TH GENERATION EGFR, ... | 1 | HKEx | ||
| 21.04. | ABBISKO-B (02256): PLACING OF NEW SHARES UNDER THE GENERAL MANDATE | 2 | HKEx | ||
| 08.04. | ABBISKO-B (02256): GRANT OF OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME AND GRANT OF RSUS UNDER THE 2019 SHARE INCENTIVE PLAN | 1 | HKEx | ||
| 31.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED ORPHAN DRUG DESIGNATION BY EMA FOR HEPATOCELLULAR CARCINOMA | 2 | HKEx | ||
| 31.03. | Abbisko Therapeutics Co., Ltd.: Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children | 118 | PR Newswire | SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 32,900 | 0,00 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| QIAGEN | 31,765 | -0,67 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 42,340 | -0,05 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,130 | 0,00 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| APOGEE THERAPEUTICS | 86,18 | -0,01 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| TYRA BIOSCIENCES | 28,550 | 0,00 % | BofA raises Tyra Biosciences stock price target on safety outlook | ||
| DISC MEDICINE | 70,09 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ABSCI | 7,270 | 0,00 % | Guggenheim hebt Kursziel für Absci auf 15 US-Dollar an - Potenzial durch Haarwuchsmittel | ||
| PRAXIS PRECISION MEDICINES | 264,54 | 0,00 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| IMMUNOVANT | 33,460 | +0,06 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,930 | +0,04 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) | ||
| COGENT BIOSCIENCES | 33,210 | +0,12 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| ERASCA | 14,430 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 15,210 | +0,13 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| BEAM THERAPEUTICS | 31,140 | +0,06 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,51 % bei einem Aktienkurs von 0,995 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.